OnKure Therapeutics

OnKure is a clinical-stage biopharmaceutical company focused on developing drugs that target specific drivers of cancer using a structure-based drug design approach. 

As of August 2023, the company had four drug candidates in its pipeline including 1) bocodepsin (OKI-179), an oral class I histone deacetylase (HDAC) inhibitor to treat hematological and solid tumors, in Phase II of clinical trials and 2) OKI-219, a selective inhibitor for PI3K alpha H1047R to treat cancer, in investigation drug stage. The company claims its lead candidate, bocodepsin, overcomes the historic limitations of the HDAC inhibitor such as poor tolerability and lack of selectivity. The company’s two other drug candidates are undisclosed targets in preclinical stages. 

Key Customers and Partnerships

In September 2020, the company partnered with Pfizer to evaluate the combination of bocodepsin and Pfizer’s binimetinib in a clinical trial collaboration and supply agreement. The company had also partnered with KDAc Therapeutics, Inc. in July 2019 to support the continued development of KDAc’s selective histone deacetylase 3 inhibitor program.

Funding and Financials

In May 2023, the company raised USD 54 million in a Series C funding round led by Surveyor Capital. The new funds were used to support the development of OnKure's pipeline of precision medicines, including advancing its lead discovery program, OKI-219, into clinical development.